Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9116554 | PMC |
| http://dx.doi.org/10.5826/dpc.1202a49 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Successful treatment of psoriasis and lichen planus with tildrakizumab.
Dermatol Online J
August 2024
Department of Dermatology, Hospital Universitario Severo Ochoa, Leganes, Madrid, Spain.
Biologics and Small Molecule Targeted Therapies for Pediatric Alopecia Areata, Psoriasis, Atopic Dermatitis, and Hidradenitis Suppurativa in the US: A Narrative Review.
Children (Basel)
July 2024
Center for Dermatology Research, Department of Dermatology, Wake Forest University School of Medicine, Winston-Salem, NC 27157, USA.
Article Synopsis
- The management of pediatric dermatological conditions has advanced with new biologics and small molecule therapies, originally approved for adults but now being evaluated for children and adolescents.
- The review aims to summarize recently FDA-approved and potential therapies for conditions like alopecia areata, psoriasis, atopic dermatitis, and hidradenitis suppurativa in pediatric patients.
- Key findings include FDA-approved treatments such as ritlecitinib for alopecia areata and multiple biologics for pediatric psoriasis and atopic dermatitis, with several others undergoing phase 3 clinical trials for potential approval.
Successful treatment of acrodermatitis continua of Hallopeau with tildrakizumab: A case report.
SAGE Open Med Case Rep
June 2023
Division of Dermatology, McGill University Health Center, Montreal, QC, Canada.
Acrodermatitis continua of Hallopeau is a rare, localized variant of pustular psoriasis commonly associated with join disease and severe quality of life impairment. While there are no standard treatment guidelines, therapies used for psoriasis vulgaris are commonly tried. We report a case of severe acrodermatitis continua of Hallopeau in a patient with multiple comorbidities (advanced malignancy, recurrent empyema, psoriatic arthritis) where tildrakizumab lead to a rapid resolution of skin and joint disease which was maintained 1 year later.
View Article and Find Full Text PDFSuccessful use of anti-IL-23 molecules in overweight-to-obese psoriatic patients: A multicentric retrospective study.
Dermatol Ther
November 2022
Department of Health Sciences, Section of Dermatology, University of Florence, Florence, Italy.
Advances in treatment with biological agents have changed the course of psoriasis. However observational reports and controlled trials draw attention to the heterogeneity of treatment response and point out that Body Mass index (BMI) may be a key factor for therapy efficacy. Therefore, we investigated the impact of BMI on the efficacy of the most recent biological molecules (anti IL-23 inhibitors) to improve patient care management.
View Article and Find Full Text PDFTildrakizumab: Successful Response in Two Patients With Psoriatic Arthritis.
Dermatol Pract Concept
May 2022
Dermatology Unit, Department of Mentals and Physical Health and Preventive medicine, University of Campania Luigi Vanvitelli, Naples, Italy.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!